Articles From: Bristol-Myers Squibb and Pfizer Announce Charitable Donations of More Than $1 Million to Support Cardiovascular Education for Patients and Caregivers to Bristow Group To Present At The Jefferies 2014 Global Energy Conference


Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced charitable donations totaling more than $1 million to be granted between 2014 and 2016 to seven nonprofit organizations that support patients with cardiovascular disease.
Sign-up for Bristol-Myers Squibb and Pfizer Announce Charitable Donations of More Than $1 Million to Support Cardiovascular Education for Patients and Caregivers investment picks
Bristol-Myers Squibb Company (NYSE:BMY) announced today the establishment of a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of combining Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor Opdivo (nivolumab) with three molecularly targeted oncology therapies ( Zykadia (ceritinib), INC280 and EGF816) from Novartis (NYSE: NVS). Novartis will conduct two Phase 1/2 studies focused on non-small cell lung cancer (NSCLC). “Bristol-Myers Squibb is committed to advancing the science, research and development of immunotherapy as an innovative approach to treating cancer in multiple tumor types,” said Michael Giordano, senior vice president, Oncology Development, Bristol-Myers Squibb.
Sign-up for Bristol-Myers Squibb Announces Collaboration to Evaluate Opdivo (nivolumab) in Combination with Targeted Therapies from Novartis to Treat Non-Small Cell Lung Cancer (NSCLC) investment picks
The Board of Directors of Bristol-Myers Squibb Company (NYSE:BMY) today declared a quarterly dividend of thirty-six cents ($0.36) per share on the $.10 par value Common Stock of the corporation.
Sign-up for Bristol-Myers Squibb Announces Dividend investment picks
The Board of Directors of Bristol-Myers Squibb Company (NYSE:BMY) today declared a quarterly dividend of thirty-seven cents ($0.37) per share on the $.10 par value Common Stock of the corporation.
Sign-up for Bristol-Myers Squibb Announces Dividend investment picks
Bristol-Myers Squibb Company (NYSE:BMY) today announced multiple regulatory milestones for Opdivo (nivolumab), an investigational PD-1 immune checkpoint inhibitor, in the U.S. and European Union.
Sign-up for Bristol-Myers Squibb Announces Multiple Regulatory Milestones for Opdivo (nivolumab) in the U.S. and European Union investment picks
Bristol-Myers Squibb Company (NYSE:BMY) and F-star Alpha Ltd.
Sign-up for Bristol-Myers Squibb Enters into Agreement that Provides an Exclusive Option to Acquire F-star Alpha Ltd. and its Novel HER2-Targeted Therapy investment picks
2014/11/10
As America prepares to salute the nation’s military veterans for their service and sacrifice, the Bristol-Myers Squibb Foundation today marked Veterans Day by announcing more than $2 million in new grants to support three leading programs that help post-9/11 veterans and their families transition from military to civilian life.
Sign-up for Bristol-Myers Squibb Foundation Awards $2 Million in New Grants to Help Veterans and their Families Transition from Military to Civilian Life investment picks
The Bristol-Myers Squibb Foundation today announced nine new grants totaling more than $3.5 million to strengthen efforts in China and India in the fight against hepatitis B virus (HBV) and hepatitis C virus (HCV) infection by focusing on the most vulnerable, high-risk patient populations.
Sign-up for Bristol-Myers Squibb Foundation Awards Nine Grants Totaling More than $3.5 Million to Support Care for High-Risk Patients with Hepatitis B and C in China and India investment picks
2014/12/1
The Bristol-Myers Squibb Foundation today marked World AIDS Day by announcing 12 new grants totaling $1.47 million that focus on strengthening community-based services in sub-Saharan Africa for adolescents and the elderly who are living with HIV and for HIV patients with comorbid female cancers or tuberculosis.
Sign-up for Bristol-Myers Squibb Foundation Marks World AIDS Day by Awarding $1.47 Million in New Grants to Strengthen HIV-Related Services in Five Sub-Saharan Countries investment picks
Bristol-Myers Squibb Company (NYSE:BMY) announced today that ten abstracts have been accepted for presentation at IDWeek 2014™, which is taking place in Philadelphia, PA, October 8-12, 2014.
Sign-up for Bristol-Myers Squibb Presents Data from Multiple New Studies at IDWeek 2014™ Showcasing Continued Innovation in Virology investment picks
Bristol-Myers Squibb Company (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for daclatasvir, an NS5A complex inhibitor, in combination with other agents for the treatment of hepatitis C (HCV). The initial daclatasvir NDA submitted to the FDA focused on its use in combination with asunaprevir, an NS3/4A protease inhibitor.
Sign-up for Bristol-Myers Squibb Receives Complete Response Letter from U.S. Food and Drug Administration for Daclatasvir, an Investigational Treatment for Hepatitis C investment picks
Bristol-Myers Squibb Company (NYSE:BMY) today reported strong financial results for the third quarter of 2014, adjusted 2014 GAAP guidance and confirmed 2014 non-GAAP guidance.
Sign-up for Bristol-Myers Squibb Reports Third Quarter 2014 Financial Results investment picks
Bristol-Myers Squibb Company (NYSE:BMY) and Galecto Biotech AB today announced that the companies, together with the Galecto shareholders, have entered into an agreement that provides Bristol-Myers Squibb the exclusive option to acquire Galecto Biotech AB and gain worldwide rights to its lead asset TD139, a novel inhaled inhibitor of galectin-3 in Phase 1 development for the treatment of idiopathic pulmonary fibrosis (IPF) and other pulmonary fibrotic conditions.
Sign-up for Bristol-Myers Squibb Signs Exclusive Option Agreement to Acquire Galecto Biotech AB and Its Novel Galectin-3 Inhibitor in Development for Idiopathic Pulmonary Fibrosis investment picks
Given the rapidly evolving hepatitis C (HCV) treatment landscape in the U.S., Bristol-Myers Squibb (NYSE:BMY) has decided that it will not pursue U.S. Food and Drug Administration (FDA) approval of the dual regimen of daclatasvir and asunaprevir for the treatment of HCV genotype 1b patients in the United States and has therefore withdrawn its new drug application (NDA) for asunaprevir, an NS3/4A protease inhibitor.
Sign-up for Bristol-Myers Squibb Statement about Asunaprevir in the U.S. investment picks
Bristol-Myers Squibb Company (NYSE:BMY) has successfully resolved all outstanding U.S. patent litigation relating to efavirenz, an active ingredient contained in our Sustiva (efavirenz) and Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate) products.
Sign-up for Bristol-Myers Squibb Statement on Sustiva (efavirenz) in the U.S. investment picks
Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the third quarter on Friday, October 24, 2014.
Sign-up for Bristol-Myers Squibb to Announce Results for Third Quarter on October 24 investment picks
Bristol-Myers Squibb Company (NYSE:BMY) today announced plans to construct a new state-of-the-art, large-scale biologics manufacturing facility in Cruiserath, County Dublin, Ireland, that will produce multiple therapies for the company’s growing biologics portfolio.
Sign-up for Bristol-Myers Squibb to Construct a New Large-Scale Biologics Manufacturing Facility in Cruiserath, Ireland investment picks
Bristol-Myers Squibb Company (NYSE:BMY) will host a teleconference on Friday, October 31, 2014, at 2:30 p.m. EDT (1:30 p.m. CDT) to review data presented at the Chicago Multidisciplinary Symposium on Thoracic Oncology (CMSTO) in Chicago.
Sign-up for Bristol-Myers Squibb to Hold Investor Teleconference to Discuss CMSTO Highlights investment picks
Bristol-Myers Squibb Company (NYSE:BMY) will present at the Credit Suisse Annual Health Care Conference on Tuesday, November 11, 2014 in Phoenix.
Sign-up for Bristol-Myers Squibb to Present at Credit Suisse 2014 Health Care Conference investment picks
Bristol-Myers Squibb Company (NYSE:BMY) announced today that 16 abstracts for Orencia were accepted for presentation at the 2014 annual meeting of the American College of Rheumatology (ACR) taking place from November 14-19, 2014 in Boston, MA.
Sign-up for Bristol-Myers Squibb to Present Sixteen Orencia (abatacept) Data Abstracts at The American College of Rheumatology (ACR) 2014 Annual Meeting investment picks
Bristol-Myers Squibb Company (NYSE:BMY) today announced it will settle $1.4 billion in pension obligations through the purchase of a group annuity contract from The Prudential Insurance Company of America (Prudential) (NYSE:PRU) for approximately 8,000 U.S. retirees and their beneficiaries who started receiving their monthly retirement benefit payments on or before June 1, 2014.
Sign-up for Bristol-Myers Squibb to Transfer $1.4 Billion in U.S. Pension Obligations to Prudential investment picks
Bristol-Myers Squibb Company (NYSE:BMY), Pharmacyclics, Inc. (NASDAQ:PCYC), and Janssen Research & Development, LLC announced today they have entered into a clinical trial collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor OPDIVO ® (nivolumab) in combination with IMBRUVICA ® (ibrutinib), an oral Bruton's tyrosine kinase (BTK) inhibitor co-developed and co-marketed by Pharmacyclics and Janssen.
Sign-up for Bristol-Myers Squibb, Pharmacyclics and Janssen Announce Clinical Collaboration to Evaluate OPDIVO® (nivolumab) and IMBRUVICA®(ibrutinib) in Non-Hodgkin Lymphoma investment picks
By Tess Stynes Bristol-Myers Squibb Co.
Sign-up for Bristol-Myers, Five Prime to Collaborate on Immunotherapy investment picks
Contracts expected to generate in excess of $2.8 billion in revenue HOUSTON , Sept.
Sign-up for Bristow Group Announces Multi-Year Contracts Including New Clients And New Markets investment picks
HOUSTON , Nov.
Sign-up for Bristow Group Announces Quarterly Dividend investment picks
- SECOND QUARTER AND SIX MONTH GAAP NET INCOME OF $26.1 MILLION ($0.73 PER DILUTED SHARE) AND $70.2 MILLION ($1.96 PER DILUTED SHARE) - SECOND QUARTER AND SIX MONTH ADJUSTED NET INCOME OF $31.1 MILLION ($0.87 PER DILUTED SHARE) AND $78.4 MILLION ($2.19 PER DILUTED SHARE) - SECOND QUARTER RESULTS IMPACTED BY NON-CASH FOREIGN CURRENCY VOLATILITY, WHILE BRISTOW VALUE ADDED AND LIQUIDITY IMPROVED - COMPANY REAFFIRMS GUIDANCE FOR FULL FISCAL YEAR 2015 ADJUSTED EPS OF $4.70 - $5.20 HOUSTON , Nov.
Sign-up for Bristow Group Reports Financial Results For Its 2015 Fiscal Second Quarter And Six Months Ended September 30, 2014 investment picks
HOUSTON , Oct.
Sign-up for Bristow Group To Present At The Jefferies 2014 Global Energy Conference investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Bristol-Myers Squibb and Pfizer Announce Charitable Donations of More Than $1 Million to Support Cardiovascular Education for Patients and Caregivers to Bristow Group To Present At The Jefferies 2014 Global Energy Conference
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent